Minirin Spray (Desmopressin Acetate)

Desmopressin acetate mimics the natural hormone vasopressin. It binds selectively to V2 receptors in the kidney’s collecting ducts, prompting the insertion of aquaporin‑2 channels that allow more water to be reabsorbed, thereby concentrating urine and lowering urine volume.

The exact dose of Minirin Spray is determined by the prescribing clinician based on the patient’s condition, age, weight, and response to therapy. Physicians typically start with the lowest effective dose and adjust as needed, following local prescribing guidelines.

Safety data for desmopressin acetate in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Healthcare providers should weigh potential benefits against risks and consider alternative therapies when treating pregnant or nursing individuals.

To order Minirin Spray, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Minirin Spray delivers desmopressin via the nasal route, offering rapid absorption and convenient dosing for patients who have difficulty swallowing tablets. Oral desmopressin tablets provide similar antidiuretic effects but may have a slower onset. Choice between nasal and oral forms depends on patient preference, adherence, and specific clinical considerations.

Store Minirin Spray at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the spray bottle tightly closed when not in use and avoid exposing it to extreme temperatures or humidity.

The spray is administered intranasally, usually one spray (10 µg) into each nostril as directed by the prescriber. Patients should prime the device if it is new, avoid blowing the nose immediately after dosing, and follow any specific instructions regarding timing relative to meals or other medications.

The most serious risks include severe hyponatremia, which can lead to seizures, coma, or cerebral edema, and water intoxication. Patients should be monitored for sudden weight gain, headache, nausea, or confusion, and serum sodium levels should be checked regularly, especially during dose adjustments.

Minirin Spray is contraindicated in individuals with known hypersensitivity to desmopressin or any component of the formulation, those with uncontrolled hyponatremia, severe renal impairment, or uncontrolled hypertension. Caution is also advised for patients with a history of water intoxication or seizure disorders.